Scleroderma
Scleroderma (systemic sclerosis) is a rare autoimmune disease characterized by hardening and tightening of the skin and connective tissues. It can be limited (primarily affecting skin) or diffuse (affecting internal organs including lungs, kidneys, heart, and GI tract). The disease involves overproduction of collagen and blood vessel abnormalities.
Prevalence
Scleroderma affects approximately 300,000 Americans. It is relatively rare, with an incidence of about 20 cases per million people per year.
Who It Affects
Women are affected 4-5 times more often than men. Most commonly diagnosed between ages 30-50. African Americans tend to have more severe disease. Risk factors include genetics and possibly certain environmental exposures.
Important: This information is for educational purposes only and does not constitute medical advice. Regenerative therapies are investigational and not FDA-approved to treat this condition.
Common Symptoms
Common Causes & Risk Factors
Traditional Treatment Options
Immunosuppressants
Medications like mycophenolate or methotrexate to slow immune-driven fibrosis.
Limitations: Variable effectiveness. Cannot reverse established fibrosis. Side effects and infection risk.
Vasodilators
Calcium channel blockers, prostacyclins, and endothelin receptor antagonists for vascular symptoms.
Limitations: Manage symptoms but don't address underlying fibrosis. Some require IV infusion.
Antifibrotic Therapy
Nintedanib approved for scleroderma-associated interstitial lung disease.
Limitations: Slows lung function decline but doesn't reverse it. GI side effects common.
Autologous Stem Cell Transplant
HSCT studied for severe, rapidly progressive disease.
Limitations: High-risk procedure. Significant treatment-related mortality. Only for select patients.
Regenerative Medicine Approach
How Regenerative Therapy May Help
Regenerative medicine for scleroderma is an area of research interest given the limited treatment options for this challenging disease. Autologous hematopoietic stem cell transplantation has been studied for severe cases. Other regenerative approaches are earlier in research for their potential antifibrotic and immunomodulatory effects.
Potential Benefits Being Studied:
- HSCT studied for severe, progressive scleroderma
- MSCs being researched for antifibrotic potential
- May help modulate immune response (under investigation)
- Research exploring effects on vascular dysfunction
- An area of need given limited treatment options
- Does not replace standard scleroderma care
Biologics Used:
Autologous hematopoietic stem cell transplant (severe cases)
Mesenchymal stem cells in clinical research
Frequently Asked Questions
What about stem cell transplant for scleroderma?
HSCT has been studied in clinical trials for severe, rapidly progressive scleroderma. The SCOT and ASTIS trials showed potential benefits but also significant risks including treatment-related deaths. It is only considered for select patients at specialized centers.
Can regenerative therapy reverse my fibrosis?
No therapy, including regenerative approaches, has been proven to reverse established fibrosis in scleroderma. Research focuses on slowing progression and modulating disease activity.
Is this appropriate for limited scleroderma?
Limited scleroderma often has a better prognosis. Aggressive therapies like HSCT are typically reserved for diffuse, rapidly progressive disease with organ involvement. Discuss your specific situation with a scleroderma specialist.
Ready to Explore Your Options?
Schedule a free consultation to discuss scleroderma and learn if regenerative medicine may be right for you.
Important Disclaimer
Regenerative therapies for scleroderma are investigational. HSCT carries significant risks and is only for select severe cases. Scleroderma requires specialized care. Work closely with a rheumatologist experienced in scleroderma.